AAM
BMRN icon

AMI Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

AMI Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-339,109
Closed -$27.9M – 90
2024
Q2 		$27.9M Sell
339,109
-7,080
-2% -$589K 1.51% 30
2024
Q1 		$30.2M Buy
346,189
+118,230
+52% +$10.6M 1.55% 32
2023
Q4 		$22M Sell
227,959
-86,669
-28% -$7.67M 1.2% 33
2023
Q3 		$27.8M Buy
+314,628
New +$28M 1.72% 29

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

AMI Asset Management's BMRN Position: Q3 2024 in Review

AMI Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 339,109 shares — an estimated $27.9M sold.

AMI Asset Management first reported a position in BMRN in Q3 2023 and held it in 4 quarters. The position peaked at $30.2M in Q1 2024. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

  • AMI Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • AMI Asset Management sold 339,109 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $27.9M.
  • AMI Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2023 and held it in 4 quarters.
  • AMI Asset Management's BioMarin Pharmaceuticals position peaked at $30.2M in Q1 2024.
  • 553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on AMI Asset Management's 13F filing for Q3 2024, filed 25 Oct 2024.